TLR2 Antagonist Polypeptides for Low-Immunogenic Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for TLR2- and TLR4-mediated sepsis, inflammatory disorders, autoimmune diseases, cancer, and transplantation rejection are inadequate, with existing therapies either ineffective or associated with significant side effects and immunogenicity issues.
Innovation Solution
Development of immunomodulatory polypeptides that specifically bind to human and murine TLR2 and TLR4 receptors, modulating their signaling pathways to reduce excessive inflammatory responses and improve graft survival and pregnancy outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to treat TLR2- and TLR4-mediated sepsis and inflammatory disorders, then treatment coverage is provided, but the therapies are ineffective or associated with significant side effects and immunogenicity issues
Solution Approach 1:
The patent employs parameter changes by modifying the amino acid sequence of the polypeptide to optimize its binding affinity to TLR2 and TLR4 receptors. By systematically varying parameters such as hydrophobicity, charge, and structural conformation through amino acid substitutions, the invention achieves enhanced therapeutic effectiveness while reducing immunogenicity and side effects compared to existing therapies
Solution Approach 2:
The invention creates a simplified copy of the natural ligand structure that interacts with TLR2 and TLR4 receptors. Instead of using complex natural ligands or large protein therapeutics, the patent develops a shortened polypeptide copy (9-31 amino acids) that replicates the essential binding features while eliminating the problematic immunogenicity and side effects associated with larger or more complex existing therapies
2Object-affected harmful factors
If short polypeptides are designed to bind TLR2 and TLR4 with low affinity, then immunogenicity is reduced, but binding effectiveness may be compromised
Solution Approach 1:
The patent resolves this contradiction through precise parameter changes in the polypeptide design. By optimizing specific amino acid positions to achieve low affinity (Kd in the micromolar range), the invention simultaneously reduces immunogenicity while maintaining sufficient binding effectiveness to modulate TLR signaling. The parameter optimization includes adjusting hydrophobicity, charge distribution, and structural flexibility to achieve the desired low-affinity binding characteristic
Solution Approach 2:
The invention applies partial action by using a shortened polypeptide sequence (9-31 amino acids) rather than full-length natural ligands. This partial sequence is sufficient to engage TLR2 and TLR4 receptors and modulate their signaling, while the reduced size and simplified structure inherently lower immunogenicity. The partial action approach achieves the therapeutic goal without the excessive complexity and immunogenicity of complete natural ligands
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptides effectively mitigate TLR-mediated inflammatory conditions and enhance transplantation success by reducing graft rejection and improving pregnancy outcomes while minimizing immunogenicity and side effects.
Implementation Method 1
short immunomodulatory polypeptides that specifically bind with low affinity to the human and murine toll-like receptors TLR2 and TLR4
Data Source
AI summary
Disclosed are immunomodulatory polypeptides that behave as weak human TLR2 agonists and as potent competitive antagonists of natural pathogenic ligands for TLR2. Also disclosed are compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including for treating sepsis or reducing the severity or likelihood of occurrence of sepsis, in the treatment of inflammatory or autoimmune diseases including rheumatoid arthritis (RA), in the treatment of atherosclerosis, in the treatment of uveitis, in cancer treatment, in organ transplantation and for reducing graft rejection and promoting fertility. Pharmaceutical compositions and kits, and treatment methods are also disclosed.